Loading…
Actuate Therapeutics, Inc. Common stock is projected to rise to $1.49 by 2027, a +23% move from its current price of $1.21. ACTU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.15 | $1.21 | $1.28 | +0.13% |
| Jul 13 | $1.12 | $1.21 | $1.31 | +0.26% |
| Jul 14 | $1.11 | $1.21 | $1.33 | +0.39% |
| Jul 15 | $1.09 | $1.22 | $1.35 | +0.52% |
| Jul 16 | $1.08 | $1.22 | $1.37 | +0.65% |
| Jul 17 | $1.07 | $1.22 | $1.39 | +0.78% |
| Jul 18 | $1.06 | $1.22 | $1.41 | +0.91% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.06 | $1.22 | $1.41 | +0.91% |
| Week 2 | $1.01 | $1.23 | $1.51 | +1.82% |
| Week 3 | $0.9718 | $1.24 | $1.59 | +2.75% |
| Week 4 | $0.944 | $1.25 | $1.67 | +3.68% |
| Week 5 | $0.9211 | $1.27 | $1.74 | +4.62% |
| Week 6 | $0.9017 | $1.28 | $1.81 | +5.57% |
| Week 7 | $0.8848 | $1.29 | $1.88 | +6.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Actuate Therapeutics, Inc. is a healthcare company described as a clinical-stage biopharmaceutical company focused on therapies for cancers in the United States. Its lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
The company also develops elraglusib in Phase 1/2 trials for refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. Actuate Therapeutics was incorporated in 2015, is headquartered in Fort Worth, Texas, and was formerly known as Apotheca Therapeutics, Inc., changing its name to Actuate Therapeutics, Inc. in October 2015.
Actuate Therapeutics, Inc. trades as ACTU in the healthcare sector. The current price is $1.23 with a market capitalization of $29.43M, and the stock holds a rank of 4,782 by market cap.
The stock shows a neutral near-term technical picture with a 30-day trading setup that appears constrained by resistance near $2.11 and supported near $1.23. The 30-day range spans $0.8537 to $1.77, highlighting limited recent upside relative to its higher historical price levels.
A major floor 47.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 71.9% above — a clean break opens room to run.
A major ceiling 176.0% above — clearing it would confirm fresh momentum.
Key ACTU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACTU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.34 | Sell | $1.32 | Sell |
| MA 10 | $1.44 | Sell | $1.45 | Sell |
| MA 20 | $1.72 | Sell | $1.65 | Sell |
| MA 50 | $2.18 | Sell | $2.05 | Sell |
| MA 100 | $2.48 | Sell | $2.74 | Sell |
| MA 200 | $4.43 | Sell | $3.99 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.85 | Buy |
| Stoch RSI (14) | 9.81 | Buy |
| CCI (20) | -122.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -37.31 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.42 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 25.33 | Buy |
| Momentum (10) | -0.75 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 1.24 | Sell |
| ADX (14) | 31.90 | Sell |
| ATR (14) | 0.09 | Info |
The near-term technical picture is evaluated as NEUTRAL, with the RSI at 30. The stock is trading below the 50-day simple moving average of $2.22 and well below the 200-day simple moving average of $4.46, indicating that momentum remains tepid and price action could stay range-bound. Support remains at $1.23 and resistance at $2.11, with the 30-day range between $0.8537 and $1.77 suggesting limited upside in the immediate horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.21 | $1.21 | $1.96 | 0% | Neutral | |
| $1.08 | $1.49 | $2.23 | +23% | Bullish | |
| $0.8861 | $1.30 | $2.06 | +7% | Neutral | |
| $0.9244 | $1.43 | $2.38 | +18% | Neutral | |
| $0.759 | $1.23 | $2.13 | +1% | Neutral | |
| $0.6556 | $1.11 | $1.99 | -8% | Neutral | |
| $0.8432 | $1.49 | $2.75 | +23% | Bullish | |
| $0.9114 | $1.67 | $3.19 | +38% | Bullish | |
| $0.9863 | $1.88 | $3.68 | +56% | Bullish | |
| $0.9484 | $1.88 | $3.76 | +56% | Bullish | |
| $1.12 | $2.49 | $5.46 | +106% | Bullish | |
| $1.53 | $3.41 | $7.84 | +182% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.21 | $1.21 | $1.51 | +0.00% |
| August 2026 | $1.11 | $1.34 | $1.69 | +10.72% |
| September 2026 | $1.11 | $1.36 | $1.75 | +1.61% |
| October 2026 | $1.07 | $1.33 | $1.75 | -1.98% |
| November 2026 | $1.11 | $1.40 | $1.86 | +4.95% |
| December 2026 | $1.15 | $1.46 | $1.96 | +4.12% |
Click any year to see its month-by-month ACTU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Actuate Therapeutics, Inc. Common stock's 2026 outlook centres on $1.21, within a $1.21 to $1.96 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACTU could reach as high as $2.23, with a base case around $1.49 and support toward $1.08 — roughly +23% from $1.21. Buyers look set to stay in control over this stretch.
Expect ACTU to range from $0.8861 to $2.06 through 2028. The $1.30 average target implies a +7% move from current prices. That is -13% versus the projected 2027 average. Price action looks broadly range-bound.
The ACTU price prediction for 2029 points to an average of $1.43 (low $0.9244, high $2.38) — a potential gain of +18% on today's $1.21. A consolidation phase looks the most probable path here.
In 2030, ACTU is projected to trade between $0.759 and $2.13, averaging $1.23 — a potential gain of +1% from today's $1.21. That is -14% versus the projected 2029 average. Price action looks broadly range-bound.
Actuate Therapeutics, Inc. Common stock's 2031 outlook centres on $1.11, within a $0.6556 to $1.99 range. That is -10% versus the projected 2030 average. That marks a -8% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ACTU could reach as high as $2.75, with a base case around $1.49 and support toward $0.8432 — roughly +23% from $1.21. Momentum favours further upside here.
Expect ACTU to range from $0.9114 to $3.19 through 2033. The $1.67 average target implies a +38% move from current prices. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACTU price prediction for 2034 points to an average of $1.88 (low $0.9863, high $3.68) — a potential gain of +56% on today's $1.21. Momentum favours further upside here.
In 2035, ACTU is projected to trade between $0.9484 and $3.76, averaging $1.88 — a potential gain of +56% from today's $1.21. That is 0% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Actuate Therapeutics, Inc. Common stock's 2040 outlook centres on $2.49, within a $1.12 to $5.46 range. That is up +32% on the projected 2035 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2050, ACTU could reach as high as $7.84, with a base case around $3.41 and support toward $1.53 — roughly +182% from $1.21. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACTU today (≈ 826.446281 ACTU) could be worth
$2,817.89
+$1,817.89 (+182%) by 2050 · US Dollar
Based on the average projected ACTU price of $3.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACTUwould be worth at today's price.
$1,000 invested in ACTU on Jul 10, 2025 (≈ 161.812302 ACTU) would be worth
$195.79
-$804.21 (-80.4%) today · 0.20× · US Dollar
Based on a ACTU entry price of $6.18 vs. today's $1.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.52 | $796.05 | -20.4% |
| 1 month ago | $1.95 | $620.51 | -37.9% |
| 3 months ago | $1.72 | $703.49 | -29.7% |
| 6 months ago | $5.75 | $210.43 | -79.0% |
| 1 year ago | $6.18 | $195.79 | -80.4% |
| All time (1.9y) ago | $8.61 | $140.53 | -85.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACTU forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $57.42M
The multi-year forecast shows a shift from neutral in the near term to more bullish momentum later in the horizon. In 2027 the average forecast price is $1.52 with a max of $2.27 and a 23.9% ROI, with a bullish sentiment. By 2030 the average is projected at $1.24 with a max of $2.16 and a 1% ROI, with neutral sentiment.
In 2031 the forecast turns softer, with an average of $1.12 and a -9% ROI, still neutral.
Tap a question to reveal the answer.
In 2027, the average forecast price is $1.52, the min is $1.11, the max is $2.27, with a 23.9% ROI and a BULLISH sentiment.
Forecasts show positive ROI in several years (e.g., 2027 23.9%, 2029 18.1%, 2032 23%, 2033 38.8%, 2040 107.3%, 2050 180.9%), but there is a negative year (2031, -9%). These are estimates and not guarantees.
Yes. The max forecast prices reach $3.25 in 2033, $3.76 in 2034, $3.84 in 2035, $5.60 in 2040, and $7.95 in 2050.
Current price is $1.23 and market capitalization is $29.43M.
The 30-day trading range is from a low of $0.8537 to a high of $1.77.
Actuate Therapeutics, Inc. Common stock Community Discussion
0Share your Actuate Therapeutics, Inc. Common stock price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.